0
$0.00

SLU-PP-332 5mg

Customer Review 0
Rated 5 out of 5

$49.99

Researched Benefits:

  • Potent pan-agonist for investigating Estrogen-Related Receptor (ERRα, ERRβ, and ERRγ) signaling.
  • Facilitates analysis of mitochondrial biogenesis and enhanced oxidative phosphorylation pathways.
  • Supports investigation into exercise-mimetic effects on skeletal muscle metabolic reprogramming.
  • Enables research on fatty acid oxidation and glucose uptake mechanisms in metabolic homeostasis models.
Share it :
Payment-Icon.png
International Shipment

Your orders are shipped seamlessly between countries

30 Days Warranty

You have the right to return your orders within 30 days.

Secure Payment

Your payments are secure with our private security network.

Description

SLU-PP-332 5mg is an investigational peptide compound under active study for its promising effects on appetite modulation, metabolic regulation, and potential anti-obesity applications. Designed with advanced peptide synthesis technologies and purified to high research-grade standards, SLU-PP-332 offers exceptional consistency and quality for scientific exploration.

Key Features:

  • Synthesized using pharmaceutical-grade manufacturing practices.

  • Every lot is rigorously tested for purity, identity, and stability.

  • Provided in lyophilized powder form for long-term research use under proper storage conditions.

Applications:

  • Research into novel mechanisms of appetite suppression and energy intake regulation.

  • Studies focused on metabolic efficiency and fat storage processes.

  • Exploration of its impact on insulin pathways and glucose control.

Specifications and Documentation

  • Material Safety Data Sheet (MSDS): Coming Soon.

  • Handling and Storage Instructions: Store in a cool, dry place. Reconstitute only in sterile agents. For research use only.

SLU-PP-332 5mg is considered a valuable tool in the scientific community for ongoing investigations into metabolic disorders and obesity-related pathways, offering insights into advanced peptide-based therapeutic strategies.

0